David Chang, Allogene (Jeff Rumans)
May 13, 2020 05:10 PM EDTUpdated 07:23 PM
R&D

Al­lo­gene spot­lights their off-the-shelf CAR-T con­tender ‘501 with a snap­shot on CRs and no GVHD

John Carroll

Editor & Founder

Al­lo­gene ex­ecs are out to rev­o­lu­tion­ize a field they played a ma­jor role in pi­o­neer­ing. And they will ar­rive — vir­tu­al­ly — at AS­CO with some …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Com­pound­ed weight loss drugs have re­sult­ed in mis­dos­ing, hos­pi­tal­iza­tions, FDA warns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times